Sugar Structures Unlocked: New Way to Block Cancer-Promoting Protein LL-37
Background
The human antimicrobial peptide LL-37 is a double-edged sword: while crucial for immunity, it paradoxically promotes the progression of various cancers, including breast cancer, by stimulating cell proliferation, migration, and angiogenesis (new blood vessel formation). Its pro-tumorigenic effects are often mediated through interactions with cell surface glycosaminoglycans (GAGs), complex sugar molecules. However, the precise structural features of GAG oligosaccharides that dictate their ability to inhibit LL-37's pro-cancerous activities have remained poorly defined.
Results
The study revealed that both the chain length and specific sulfation patterns of GAG oligosaccharides are critical for potent LL-37 inhibition. A heparan sulfate hexasaccharide featuring a specific N-sulfation and 6-O-sulfation pattern emerged as the most potent inhibitor, demonstrating an IC50 of 25 nM against LL-37's binding to cancer cells, representing a remarkable 5-fold increase in potency compared to less sulfated or shorter GAG counterparts. This optimized hexasaccharide significantly reduced LL-37-induced VEGF secretion by 43% in MDA-MB-231 breast cancer cells at a concentration of 100 nM, a statistically significant reduction compared to control GAGs (p<0.001). Furthermore, molecular docking simulations corroborated these findings, indicating a stronger binding affinity (Kd of approximately 5 nM) for the optimized hexasaccharide to LL-37's active site, contrasting sharply with a Kd of approximately 50 nM for less sulfated structures. Conversely, chondroitin sulfate oligosaccharides, even with similar lengths, showed significantly lower inhibitory activity, highlighting the specificity of heparan sulfate structures.
Why It Matters
This research provides crucial insights into the molecular mechanisms by which GAGs can modulate LL-37 activity, identifying specific structural features that confer potent inhibitory effects. This understanding is a significant step towards developing novel therapeutic strategies for breast cancer and other cancers where LL-37 plays a pro-tumorigenic role. The identification of these optimized GAG oligosaccharide structures could lead to the design of highly targeted, non-toxic drugs to block LL-37's cancer-promoting actions. Future research will focus on validating these findings in relevant in vivo animal models and further optimizing these GAG mimetics for potential clinical translation, potentially moving towards Phase I human trials.